{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T13:03:11Z","timestamp":1765285391787,"version":"3.46.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.urolonc.2025.09.025","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T02:39:43Z","timestamp":1761619183000},"page":"65.e1-65.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5954-3278","authenticated-orcid":false,"given":"Tanya","family":"Jindal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy Y.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Alhalabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Davidsohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dory","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilana Y.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitra Rafailia","family":"Bakaloudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafee","family":"Talukder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Nizam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles B.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Tsung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Glover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Raza","family":"Khaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy K.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"Jaime-Casas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Lemke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron","family":"Pywell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean T.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denny","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet A.","family":"Bilen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnab","family":"Basu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Kilari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhishek","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Emamekhoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy B.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumit","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajjai","family":"Alva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew T.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-8668","authenticated-orcid":false,"given":"Vadim S.","family":"Koshkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.urolonc.2025.09.025_bib0001","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2025.09.025_bib0002","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.025_bib0003","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2025.09.025_bib0004","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.urolonc.2025.09.025_bib0005","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.urolonc.2025.09.025_bib0006","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.urolonc.2025.09.025_bib0007","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2025.09.025_bib0008","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.urolonc.2025.09.025_bib0009","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"New Engl J Med"},{"issue":"22","key":"10.1016\/j.urolonc.2025.09.025_bib0010","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of Sacituzumab Govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.urolonc.2025.09.025_bib0011","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: a phase I study of single-agent Enfortumab Vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.urolonc.2025.09.025_bib0012","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of Enfortumab Vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2025.09.025_bib0013","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of Trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"JCO"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2025.09.025_bib0014","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4565","article-title":"Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study","volume":"42","author":"Wysocki","year":"2024","journal-title":"JCO"},{"issue":"10","key":"10.1016\/j.urolonc.2025.09.025_bib0015","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.urolonc.2025.09.025_bib0016","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus Gemcitabine\u2013Cisplatin in advanced urothelial carcinoma","volume":"389","author":"der","year":"2023","journal-title":"New Engl J Med"},{"issue":"8","key":"10.1016\/j.urolonc.2025.09.025_bib0017","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/14712598.2017.1331214","article-title":"Sacituzumab govitecan: an antibody-drug conjugate","volume":"17","author":"Sahota","year":"2017","journal-title":"Expert Opin Biol Ther"},{"issue":"19","key":"10.1016\/j.urolonc.2025.09.025_bib0018","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"issue":"29","key":"10.1016\/j.urolonc.2025.09.025_bib0019","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.23.01720","article-title":"TROPHY-U-01 cohort 2: a phase II study of Sacituzumab Govitecan in cisplatin-ineligible patients with metastatic urothelial cancer progressing after previous checkpoint inhibitor therapy","volume":"42","author":"Petrylak","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2025.09.025_bib0020","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.22.02835","article-title":"Sacituzumab Govitecan in combination with Pembrolizumab for patients with metastatic urothelial cancer that progressed after platinum-based chemotherapy: TROPHY-U-01 cohort 3","volume":"42","author":"Grivas","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.09.025_bib0021","unstructured":"bladder.pdf. Accessed March 26, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/bladder.pdf"},{"key":"10.1016\/j.urolonc.2025.09.025_bib0022","doi-asserted-by":"crossref","first-page":"S1505","DOI":"10.1016\/j.annonc.2024.10.830","article-title":"LBA9 TROPiCS-04, a randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (CT) in pretreated advanced urothelial carcinoma (aUC): overall survival (OS) and safety analysis","volume":"35","author":"Grivas","year":"2024","journal-title":"Ann Oncol"},{"issue":"0","key":"10.1016\/j.urolonc.2025.09.025_bib0023","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"0","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"issue":"5_suppl","key":"10.1016\/j.urolonc.2025.09.025_bib0024","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.5_suppl.770","article-title":"Survey-based study of treatment sequencing after first-line (1L) enfortumab vedotin\/pembrolizumab (EVP) in the evolving landscape of locally advanced\/metastatic (la\/m) urothelial cancer (UC)","volume":"43","author":"Chablani","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.urolonc.2025.09.025_bib0025","doi-asserted-by":"crossref","first-page":"S1271","DOI":"10.1016\/j.annonc.2024.08.2327","article-title":"LBA5 A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA)","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2025.09.025_bib0026","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","article-title":"TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes","volume":"35","author":"Loriot","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2025.09.025_bib0027","unstructured":"Gilead provides update on U.S. Indication for Trodelvy\u00ae in metastatic urothelial cancer. Accessed February 7, 2025.https:\/\/www.gilead.com\/company\/company-statements\/2024\/gilead-provides-update-on-us-indication-for-trodelvy-in-metastatic-urothelial-cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2025.09.025_bib0028","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.euf.2024.05.011","article-title":"Therapies after progression on Enfortumab Vedotin and Pembrolizumab: navigating second-line options for metastatic urothelial carcinoma in the new treatment landscape","volume":"10","author":"Brown","year":"2024","journal-title":"Euro Urol Focus"},{"issue":"21","key":"10.1016\/j.urolonc.2025.09.025_bib0029","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"New Engl J Med"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2025.09.025_bib0030","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.523","article-title":"Evaluation of clinical benefit of sacituzumab govitecan (SG) following enfortumab vedotin (EV) in advanced urothelial cancer (UC): real-world experience","volume":"41","author":"Vlachou","year":"2023","journal-title":"JCO"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2025.09.025_bib0031","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4581","article-title":"Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC)","volume":"42","author":"Sternschuss","year":"2024","journal-title":"JCO"},{"issue":"6","key":"10.1016\/j.urolonc.2025.09.025_bib0032","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.euo.2021.11.005","article-title":"TROP2 Expression across molecular subtypes of urothelial carcinoma and enfortumab vedotin-resistant cells","volume":"5","author":"Chou","year":"2022","journal-title":"Eur Urol Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925003953?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925003953?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T12:59:15Z","timestamp":1765285155000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925003953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1078143925003953"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.09.025","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}